Pharmalot -- Two weeks ago, the House Energy & Commerce Committee stepped up its probe of the controversial cholesterol pill by demanding Merck and Schering-Plough, which jointly market Vytorin, turn over documents relating to the SEAS trial and its analysis. This trial, you may recall, turned up an unexpected link to cancer and cancer-related deaths (back story).
